Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × spartalizumab × Clear all

Phase

Phase 1 18 Phase 2 11 Phase 1/2 6 Phase EARLY_PHASE1 1 Phase 3 1

Status

Unknown 4 Recruiting 4 Withdrawn 3 Not yet recruiting 3 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

Cisplatin 50 Carboplatin 45 Radiotherapy 41 Paclitaxel 40 Docetaxel 38 Gemcitabine 33 Cyclophosphamide 32 Rituximab 29 Fluorouracil 26 Dexamethasone 25 Capecitabine 25 Doxorubicin 24 Prednisone 20 Bevacizumab 19 Oxaliplatin 17 Leucovorin 17 Vincristine 15 Etoposide 15 Cytarabine 15 pembrolizumab 13 Pemetrexed 13 Imatinib Mesylate 13 Drug Therapy 13 Zoledronic Acid 12 Radiosurgery 12 Irinotecan 12 Filgrastim 12 Erlotinib Hydrochloride 11 Surgical Procedures, Operative 10 Standard of Care 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡